Marina V Shestakova

List of Publications by Citations

155 papers	2,080 citations	23 h-index	42 g-index
198 ext. papers	2,592 ext. citations	2.5 avg, IF	5.15 L-index

#	Paper	IF	Citations
155	The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. *Diabetes Care*, **2013**, 36, 858-64	14.6	186
154	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. *Diabetes Mellitus*, **2019**, 22, 1-121	1.6	139
153	Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1637-45	5.6	126
152	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. *Diabetes Mellitus*, **2017**, 20, 1-121	1.6	109
151	The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). *Diabetes Mellitus*, **2016**, 19, 104-112	1.6	95
150	Electrode materials used for electrochemical oxidation of organic compounds in wastewater. *Reviews in Environmental Science and Biotechnology*, **2017**, 16, 223-238	13.9	80
149	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). *Cardiovascular Diabetology*, **2018**, 17, 150	8.7	73
148	Removal of carbamazepine from MBR effluent by electrochemical oxidation (EO) using a Ti/Ta2O5-SnO2 electrode. *Applied Catalysis B: Environmental*, **2018**, 221, 329-338	21.8	72
147	Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). *Obesity and Metabolism*, **2018**, 15, 53-70	0.6	72
146	Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. *Diabetes Mellitus*, **2018**, 21, 144-159	1.6	62
145	Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2. *Journal of Translational Medicine*, **2014**, 12, 337	8.5	53
144	Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). *Diabetes Research and Clinical Practice*, **2016**, 115, 90-5	7.4	48
143	Removal of dichloromethane from ground and wastewater: a review. *Chemosphere*, **2013**, 93, 1258-67	8.4	46
142	National register of diabetes mellitus in Russian Federation.. *Diabetes Mellitus*, **2015**, 18, 5-22	1.6	45
141	Regulation of Adipose Tissue Stem Cells Angiogenic Potential by Tumor Necrosis Factor-Alpha. *Journal of Cellular Biochemistry*, **2016**, 117, 180-96	4.7	39
140	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. *Journal of Diabetes and Its Complications*, **2017**, 31, 1188-1196	3.2	37
139	Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies. *Diabetes Mellitus*, **2017**, 20, 220-230	1.6	37

138	Adiponectin and adiponectin receptor gene variants in relation to type 2 diabetes and insulin resistance-related phenotypes. *Review of Diabetic Studies*, **2008**, 5, 28-37	3.6	36
137	Sonoelectrocatalytic decomposition of methylene blue using Ti/Ta□□5SnO□electrodes. *Ultrasonics Sonochemistry*, **2015**, 23, 135-41	8.9	31
136	Novel Ti/Ta2O5-SnO2 electrodes for water electrolysis and electrocatalytic oxidation of organics. *Electrochimica Acta*, **2014**, 120, 302-307	6.7	31
135	Contraception in perimenopausal women with diabetes mellitus. *Gynecological Endocrinology*, **2006**, 22, 198-206	2.4	31
134	Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. *Diabetes Mellitus*, **2021**, 24, 204-221	1.6	29
133	Electrochemical Water Treatment Methods **2017**, 47-130		23
132	Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. *Diabetes Research and Clinical Practice*, **2005**, 68 Suppl1, S65-72	7.4	21
131	Photoelectrocatalytic activity of ZnO coated nano-porous silicon by atomic layer deposition. *RSC Advances*, **2016**, 6, 25173-25178	3.7	20
130	Sonoelectrochemical degradation of formic acid using Ti/Ta 2 O 5 -SnO 2 electrodes. *Journal of Molecular Liquids*, **2016**, 223, 388-394	6	19
129	Diagnosing impaired glucose tolerance using direct infusion mass spectrometry of blood plasma. *PLoS ONE*, **2014**, 9, e105343	3.7	19
128	The PPARgamma Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects. *Diabetes and Vascular Disease Research*, **2010**, 7, 56-62	3.3	19
127	Contrast-induced nephropathy in patients with type 2 diabetes during coronary angiography: risk-factors and prognostic value. *Diabetes Research and Clinical Practice*, **2009**, 86 Suppl 1, S63-9	7.4	18
126	Eco-friendly bleaching of indigo dyed garment by advanced oxidation processes. *Journal of Cleaner Production*, **2017**, 158, 134-142	10.3	17
125	Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23-q24 by association study in Russian type 1 diabetic patients. *Diabetes Research and Clinical Practice*, **2004**, 66, 79-86	7.4	17
124	Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. *Diabetes Mellitus*, **2016**, 19, 518-527	1.6	16
123	Effectiveness of gliclazide MR 60□mg in the management of type 2 diabetes: analyses from the EASYDia trial. *Diabetology and Metabolic Syndrome*, **2018**, 10, 30	5.6	15
122	Molecular Mechanisms of Latent Inflammation in Metabolic Syndrome. Possible Role of Sirtuins and Peroxisome Proliferator-Activated Receptor Type □*Biochemistry (Moscow)*, **2015**, 80, 1217-26	2.9	14
121	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. *Diabetes Mellitus*, **2019**, 22, 1-121	1.6	14

120	Trends in the epidemiology of diabetic retinopathy in Russian Federation according to the Federal Diabetes Register (2013–2016). *Diabetes Mellitus*, **2018**, 21, 230-240	1.6	14
119	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. *Diabetes Research and Clinical Practice*, **2018**, 146, 240-250	7.4	14
118	Optimization of Ti/Ta2O5–SnO2 electrodes and reaction parameters for electrocatalytic oxidation of methylene blue. *Journal of Applied Electrochemistry*, **2016**, 46, 349-358	2.6	12
117	Trends in the epidemiology of diabetic foot and lower limb amputations in Russian Federation according to the Federal Diabetes Register (2013–2016). *Diabetes Mellitus*, **2018**, 21, 170-177	1.6	11
116	Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013–2016). *Diabetes Mellitus*, **2018**, 21, 160-169	1.6	10
115	LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. *Journal of Hypertension*, **2016**, 34, 1140-50	1.9	10
114	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). *Cardiovascular Diabetology*, **2017**, 16, 137	8.7	9
113	Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. *Current Medical Research and Opinion*, **2009**, 25, 2643-54	2.5	9
112	Diabetes mellitus type 2 in adults. *Diabetes Mellitus*, **2020**, 23, 4-102	1.6	9
111	Type 2 diabetes and metabolic syndrome: identification of the molecular mechanisms, key signaling pathways and transcription factors aimed to reveal new therapeutical targets. *Diabetes Mellitus*, **2018**, 21, 364-375	1.6	9
110	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. *Diabetes Research and Clinical Practice*, **2016**, 112, 50-56	7.4	8
109	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. *Russian Journal of Cardiology*, **2019** , 83-91	1.3	8
108	Study design and baseline characteristics of patients in the PRESENT study. *Diabetes Research and Clinical Practice*, **2008**, 81 Suppl 1, S3-9	7.4	7
107	The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications. *Diabetes Mellitus*, **2010**, 13, 14-19	1.6	7
106	Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion. *Russian Journal of Cardiology*, **2019**, 44-51	1.3	7
105	Association of FTO, KCNJ11, SLC30A8, and CDKN2B polymorphisms with type 2 diabetes mellitus. *Molecular Biology*, **2015**, 49, 103-111	1.2	6
104	Metabolic characteristics and therapeutic potential of brown and ?beige? adipose tissues. *Diabetes Mellitus*, **2014**, 17, 5-15	1.6	6
103	Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. *Diabetes Mellitus*, **2022**, 25, 27-49	1.6	6

102	Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. *Archives of Drug Information*, **2009**, 2, 23-33		5
101	The clinical and epidemiological characteristics of hypogonadism in men with type 2 diabetes mellitus. *Diabetes Mellitus*, **2019**, 22, 536-541	1.6	5
100	Circulating precursors of endothelial cells in patients with CHD and disturbed carbohydrate metabolism. *Diabetes Mellitus*, **2010**, 13, 13-20	1.6	5
99	Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients. *Diabetes Research and Clinical Practice*, **2019**, 158, 107928	7.4	5
98	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. *Terapevticheskii Arkhiv*, **2022**, 94, 216-253	0.9	5
97	Multidisciplinary lifestyle management approach in patients with type 2 diabetes mellitus in real clinical practice. Results of application «life is easy» programme in Russia. *Diabetes Mellitus*, **2019**, 22, 115-126	1.6	4
96	Epidemiology of acute diabetes complications (coma) according to the Federal Diabetes register of the Russian Federation (2013–2016). *Diabetes Mellitus*, **2018**, 21, 444-454	1.6	4
95	DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS. *Diabetes Mellitus*, **2019**, 22, 592-601	1.6	4
94	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis. *Diabetes Mellitus*, **2019**, 22, 504-514	1.6	4
93	Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. *Diabetes Mellitus*, **2019**, 22, 305-327	1.6	4
92	Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA». *Obesity and Metabolism*, **2018**, 15, 48-58	0.6	4
91	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. *American Heart Journal*, **2022**, 243, 232-239	4.9	4
90	Sakharnyy diabet 2 tipa i kognitivnye narusheniya. *Diabetes Mellitus*, **2008**, 11, 61-66	1.6	4
89	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 39-48	6.7	4
88	Mass spectrometry analysis of blood plasma lipidome as the method of disease diagnostics, evalution of effectiveness and optimization of drug therapy. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry*, **2015**, 9, 95-105	0.4	3
87	TCF7L2 rs12255372 and SLC30A8 rs13266634 confer susceptibility to type 2 diabetes in a Russian population. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2009**, 3, 219-223	8.9	3
86	The KCNJ11 E23K and ABCC8 exon 31 variants contribute to susceptibility to type 2 diabetes, glucose intolerance and altered insulin secretion in a Russian population. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, **2008**, 2, 185-191	8.9	3
85	Insulin degludec is a new ultra-long-acting insulin analogue. *Diabetes Mellitus*, **2014**, 17, 91-104	1.6	3

84	The prevalence of hypogonadism in men with type 2 diabetes mellitus in clinical practice. *Diabetes Mellitus*, **2019**, 22, 127-130	1.6	3
83	Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL. *Diabetes Mellitus*, **2011**, 14, 75-80	1.6	3
82	New prospects in the treatment of diabetes mellitus. *Diabetes Mellitus*, **2012**, 15, 109-114	1.6	3
81	Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. *Diabetes Mellitus*, **2013**, 16, 97-102	1.6	3
80	The role of mineral and bone disorders in the development and progression of cardiac and renal pathology in patients with type 1 diabetes mellitus of long duration. *Diabetes Research and Clinical Practice*, **2016**, 118, 29-37	7.4	3
79	DIARISK the first national prediabetes and diabetes mellitus type 2 risk calculator. *Diabetes Mellitus*, **2021**, 23, 404-411	1.6	3
78	Ultrasound-assisted electrochemical treatment of wastewaters containing organic pollutants by using novel Ti/Ta2O5SnO2 electrodes **2020**, 79-161		2
77	The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus. *Diabetes Mellitus*, **2010**, 13, 106-109	1.6	2
76	Obesity - a risk factor of renal pathology in patients with type 2 diabetes mellitus. *Diabetes Mellitus*, **2010**, 13, 45-49	1.6	2
75	Epidemiology of cardiovascular diseases among patients with diabetes mellitus according to the federal diabetes register of the Russian Federation (20132016). *Diabetes Mellitus*, **2019**, 22, 105-114	1.6	2
74	The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2. *Diabetes Mellitus*, **2019**, 22, 253-262	1.6	2
73	COVID-19 and kidneys. *Diabetes Mellitus*, **2020**, 23, 235-241	1.6	2
72	Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation. *Diabetes Mellitus*, **2017**, 20, 233-237	1.6	2
71	Guidelines for the Diagnosis and Treatment of testosterone deficiency (hypogonadism) in male patients with diabetes mellitus. *Obesity and Metabolism*, **2017**, 14, 83-92	0.6	2
70	Hyperglycemia and possible mechanisms of cell damage in patients with COVID-19. *Diabetes Mellitus*, **2020**, 23, 229-234	1.6	2
69	Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity. *Obesity and Metabolism*, **2015**, 12, 16-19	0.6	2
68	Intraperitoneal insulin infusion: on the way to the artificial pancreas. *Diabetes Mellitus*, **2015**, 18, 32-45	1.6	2
67	Pharmacogenetics of hypoglycemic agents. *Diabetes Mellitus*, **2015**, 18, 28-34	1.6	2

66	Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease. *Diabetes Mellitus*, **2016**, 19, 24-29	1.6	2
65	Association of polymorphism rs7903146 gene TCF7L2 with low concentrations of autoantibodies in latent autoimmune diabetes of adults (LADA). *Diabetes Mellitus*, **2016**, 19, 199-203	1.6	2
64	The role of «metabolic memory» mechanisms in the development and progression of vascular complications of diabetes mellitus. *Diabetes Mellitus*, **2017**, 20, 126-134	1.6	2
63	Biosimilars: presumption of guilt. *Diabetes Mellitus*, **2011**, 14, 91-99	1.6	2
62	Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow. *Diabetes Mellitus*, **2012**, 15, 101-109	1.6	2
61	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). *Eurasian Heart Journal*, **2021**, 6-61	0.7	2
60	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1956-1960	6.7	2
59	Predictors of postprandial blood glucose response to biphasic insulin analogue therapy. *Primary Care Diabetes*, **2013**, 7, 63-7	2.4	1
58	Replication of association between polymorphisms of the pancreatic ATP-sensitive potassium channel and susceptibility to type 2 diabetes in two Russian urban populations. *Open Life Sciences*, **2010**, 5, 67-77	1.2	1
57	Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. *Diabetes Mellitus*, **2022**, 24, 479-486	1.6	1
56	Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. *Diabetes Mellitus*, **2020**, 23, 349-356	1.6	1
55	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues. *Diabetes Mellitus*, **2014**, 17, 108-119	1.6	1
54	Features of carbohydrate metabolism and incretin secretion in patients with Cushing disease and acromegaly. *Diabetes Mellitus*, **2017**, 20, 249-256	1.6	1
53	TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity. *Obesity and Metabolism*, **2017**, 14, 38-42	0.6	1
52	Chronic kidney disease complications in patients with type 1 diabetes mellitus after simultaneous pancreas-kidney transplantation – potential role of oxidative stress and glycation end products. *Diabetes Mellitus*, **2019**, 22, 405-416	1.6	1
51	Sovremennoe ponyatie?khronicheskaya bolezn' pochek?: metody diagnostiki, klinicheskoe znachenie. *Diabetes Mellitus*, **2008**, 11, 4-7	1.6	1
50	Is Absence of Carbohydrate Metabolism Disorders in Patients with Prolonged History of Obesity due to Low Insulin Resistance or Preserved Insulin Secretion?. *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk*, **2018**, 73, 344-353	0.4	1
49	Clinical, pathomorphological and immunohistochemical evaluation of tissue repair in diabetic foot ulcers. *Diabetes Mellitus*, **2018**, 21, 490-496	1.6	1

48	Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. *Diabetes Mellitus*, **2019**, 22, 159-164	1.6	1
47	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. *Russian Journal of Cardiology*, **2020**, 25, 3919	1.3	1
46	Podocyte injury in diabetes mellitus. *Diabetes Mellitus*, **2014**, 17, 39-50	1.6	1
45	Evaluation of biocompatibility of an experimental membrane for glucose sensors: the results of a prospective experimental controlled preclinical study involving laboratory animals. *Problemy Endokrinologii*, **2017**, 63, 219-226	0	1
44	Factors of tubulointerstitial lesions in diabetic kidneys. *Diabetes Mellitus*, **2009**, 12, 61-65	1.6	1
43	The results of open observational trial DIAMOND. *Diabetes Mellitus*, **2011**, 14, 96-102	1.6	1
42	Simultaneous pancreas-kidney transplantation: Pro et Contra. *Diabetes Mellitus*, **2011**, 14, 32-37	1.6	1
41	Cardiorenal syndrome in patients with chronic kidney disease and diabetes mellitus. *Diabetes Mellitus*, **2013**, 16, 90-96	1.6	1
40	Identifying the unmet needs of individuals with Type 2 diabetes: an international web-based survey. *Journal of Comparative Effectiveness Research*, **2021**, 10, 613-624	2.1	1
39	Prospects for the use of fecal microbiota transplantation in obese patients with Type 2 Diabetes Mellitus for weight loss and improvement of insulin sensitivity. *Diabetes Mellitus*, **2021**, 23, 541-547	1.6	1
38	High level of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. *Diabetes Mellitus*, **2021**, 23, 504-513	1.6	1
37	Early functional and microcirculatory changes in patients with type 1 diabetes mellitus and no apparent diabetic retinopathy. *Diabetes Mellitus*, **2021**, 24, 243-250	1.6	1
36	Time in range is a tool for assessing the quality of glycemic control in diabetes. *Diabetes Mellitus*, **2021**, 24, 282-290	1.6	1
35	Vaccination of patients with diabetes mellitus. *Diabetes Mellitus*, **2022**, 25, 50-60	1.6	1
34	Sulfur containing acyclovir derivatives: synthesis, cytotoxic activity, and cell phenotype studies. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 1269-71	1.4	0
33	Genetic parameters of wound healing in patients with neuropatic diabetic foot ulcers. *Diabetes Mellitus*, **2017**, 20, 344-349	1.6	0
32	The effect of bariatric surgery on purine metabolism and gout. *Obesity and Metabolism*, **2020**, 17, 138-146	0.6	0
31	The significance of circulating progenitor cells with osteogenic activity in the of atherosclerosis development in patients with type 2 diabetes mellitus. *Obesity and Metabolism*, **2019**, 16, 62-69	0.6	0

30	The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus. *Diabetes Mellitus*, **2020**, 23, 242-249	1.6	0
29	Guidelines for the diagnosis and treatment of testosterone deficiency (hypogonadism) in male patients with diabetes mellitus (Draft). *Diabetes Mellitus*, **2017**, 20, 151-160	1.6	0
28	Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?. *Diabetes Mellitus*, **2017**, 20, 108-118	1.6	0
27	The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?. *Current Molecular Medicine*, **2021**, 21, 527-538	2.5	0
26	Oral semaglutide: the innovation in type 2 diabetes management. *Diabetes Mellitus*, **2021**, 24, 273-281	1.6	0
25	Advanced glycation end products and oxidative stress as a basis for metabolic abnormalities in patients with type 1 diabetes after successful simultaneous pancreas-kidney transplantation. *Terapevticheskii Arkhiv*, **2021**, 93, 1155-1163	0.9	
24	Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day. *Terapevticheskii Arkhiv*, **2021**, 93, 1203-1208	0.9	
23	Relationship between telomerase activity and parameters of carbohydrate metabolism and vascular wall. *Cardiovascular Therapy and Prevention (Russian Federation)*,18, 33-39	0.9	
22	The role of advanced glycation end products in patogenesis of diabetic nephropathy. *Diabetes Mellitus*, **2022**, 24, 461-469	1.6	
21	Possibilities of predicting preclinical forms of cardiovascular diseases in young patients with type 1 diabetes mellitus using cardiac magnetic resonance imaging. *Sibirskij Žurnal Klinič̈eskoj I Ėksperimental?noj Mediciny*, **2021**, 36, 51-58	0.3	
20	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review. *Diabetes Mellitus*, **2018**, 21, 206-216	1.6	
19	Genetic Variants Associated with the Development of Type 2 Diabetes: Approaches to Their Identification. *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk*, **2019**, 74, 44-53	0.4	
18	Relationship between telomerase activity and parameters of carbohydrate metabolism and vascular wall. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2019**, 18, 33-39	0.9	
17	Simultaneous pancreas-kidney transplantation in type 1 diabetes mellitus. Clinical options. *Diabetes Mellitus*, **2020**, 23, 275-282	1.6	
16	Post-transplantation diabetes mellitus: an overview. *Diabetes Mellitus*, **2015**, 18, 20-31	1.6	
15	[illegible] *Diabetes Mellitus*, **2015**, 18, 51-56	1.6	
14	Comparative analysis of glycemic control effectiveness and microvascular complications in patients with type 1 diabetes mellitus, treated with genetically engineered human insulin or human insulin analogues: A 10-year retrospective observational study. *Diabetes Mellitus*, **2016**, 19, 388-396	1.6	
13	Liraglutid - vozmozhnosti kompleksnogo terapevticheskogo podkhoda v terapii SD 2 tipa. *Diabetes Mellitus*, **2009**, 12, 3-6	1.6	

12	Friedreichs ataxia in a diabetic patient. *Diabetes Mellitus*, **2010**, 13, 120-124	1.6
11	New indications for exenatide therapy of type 2 diabetes mellitus. *Diabetes Mellitus*, **2010**, 13, 98-104	1.6
10	Glibenclamide therapy: pros and cons. *Diabetes Mellitus*, **2011**, 14, 92-96	1.6
9	Incretin-based therapy in patients with type 2 diabetes and chronic kidney disease. *Diabetes Mellitus*, **2012**, 15, 59-66	1.6
8	Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive. *Diabetes Mellitus*, **2012**, 15, 115-121	1.6
7	Early insulin therapy Coordination Council. *Diabetes Mellitus*, **2012**, 15, 128-131	1.6
6	Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48-week, multicenter, non-randomized, parallel-group, open-label study. *Obesity Science and Practice*, **2021**, 7, 368-378	2.6
5	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment. *Diabetes Mellitus*, **2021**, 24, 193-197	1.6
4	On the centenary of the insulin discovery. *Diabetes Mellitus*, **2021**, 24, 11-16	1.6
3	The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists. *Diabetes Mellitus*, **2021**, 24, 175-184	1.6
2	Adrenal incidentaloma. Part 2. Modern concepts of computed tomography semiotics of adrenal gland incidentalomas: algorithm of differential diagnosis. *Terapevticheskii Arkhiv*, **2021**, 93, 1381-1388	0.9
1	Type 2 Diabetes Mellitus Facilitates Shift of Adipose-Derived Stem Cells Ex Vivo Differentiation toward Osteogenesis among Patients with Obesity. *Life*, **2022**, 12, 688	3